Who Exports Sulfadoxine from India — 41 Suppliers Behind a $54.0M Market
India's sulfadoxine export market is supplied by 41 active exporters who collectively shipped $54.0M across 364 shipments. S KANT HEALTHCARE LIMITED leads with a 69.5% market share, followed by MACLEODS PHARMACEUTICALS LTD and GRACURE PHARMACEUTICALS LIMITED. The top 5 suppliers together control 84.1% of total export value, reflecting a concentrated market structure.
Top Sulfadoxine Exporters from India — Ranked by Export Value
S KANT HEALTHCARE LIMITED is the leading sulfadoxine exporter from India, holding a 69.5% share of the $54.0M market across 364 shipments from 41 exporters. The top 5 suppliers — S KANT HEALTHCARE LIMITED, MACLEODS PHARMACEUTICALS LTD, GRACURE PHARMACEUTICALS LIMITED, S K AGE EXPORTS, MEDOPHARM — collectively control 84.1% of total export value, indicating a highly concentrated market. Individual shares are: S KANT HEALTHCARE LIMITED (69.5%), MACLEODS PHARMACEUTICALS LTD (7.4%), GRACURE PHARMACEUTICALS LIMITED (2.9%), S K AGE EXPORTS (2.2%), MEDOPHARM (2.1%).
Top Sulfadoxine Exporters from India
Ranked by export value · 41 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | S KANT HEALTHCARE LIMITED LARIDOXH/M-AMODIAQUINE 150MG+SULFADOXINE/PYRIMEH/M-AMODIAQUINE 150MG +SULFADOXINE/PYRIM | $37.5M | 18 | 69.5% |
| 2 | MACLEODS PHARMACEUTICALS LTD H/M-AMODIAQUINE 150MG+SULFADOXINE/PYRIMELARIDOXAMODIAQUINE 75MG+SULFADOXINE/PYRIMETHAMI | $4.0M | 12 | 7.4% |
| 3 | GRACURE PHARMACEUTICALS LIMITED MALOXINE B/50X3 TABLETS ( SULFADOXINE USMALOXINE B/50X3 TABLETS( SULFADOXINE USPMALOXINE B/50X3 TABLETS | $1.6M | 1 | 2.9% |
| 4 | S K AGE EXPORTS LARIDOXH/M-AMODIAQUINE 150MG+SULFADOXINE/PYRIMEH/M-AMODIAQUINE 150MG +SULFADOXINE/PYRIM | $1.2M | 3 | 2.2% |
| 5 | MEDOPHARM | $1.1M | 4 | 2.1% |
| 6 | LABORATE PHARMACEUTICALS INDIA LTD H/M-AMODIAQUINE 150MG +SULFADOXINE/PYRIMAMODIAQUINE 75MG+SULFADOXINE/PYRIMETHAMI | $1.0M | 1 | 1.9% |
| 7 | SHALINA LABORATORIES PRIVATE LIMITED | $574.8K | 9 | 1.1% |
| 8 | MEDOPHARM PRIVATE LIMITED | $262.7K | 1 | 0.5% |
| 9 | SHALINA LABORATORIES PVT LTD | $170.2K | 3 | 0.3% |
| 10 | UNILINK PHARMA PRIVATE LIMITED LARIDOXSULFADOXINE & PYRIMETHAMINE TABLETS USP( | $146.3K | 1 | 0.3% |
| 11 | MACLEODS PHARMACEUTICALS LIMITED H/M-AMODIAQUINE 150MG+SULFADOXINE/PYRIMELARIDOXAMODIAQUINE 75MG+SULFADOXINE/PYRIMETHAMI | $117.2K | 4 | 0.2% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Sulfadoxine exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| MACLEODS PHARMACEUTICALS LIMITED | Not Listed | Yes, as of 2021 | Yes | Not verified | WHO-GMP certified as of 2021; EU GMP compliance confirmed. |
| GRACURE PHARMACEUTICALS LIMITED | Not Listed | Yes, as of 2021 | No | Not verified | WHO-GMP certified as of 2021; no EU GMP certification found. |
| MEDOPHARM PRIVATE LIMITED | Not Listed | Yes, as of 2021 | Yes | Not verified | WHO-GMP certified as of 2021; EU GMP compliance confirmed. |
| SHALINA LABORATORIES PRIVATE LIMITED | Not Listed | Yes, as of 2021 | No | Not verified | WHO-GMP certified as of 2021; no EU GMP certification found. |
| S KANT HEALTHCARE LIMITED | Not Listed | Yes, as of 2021 | No | Not verified | WHO-GMP certified as of 2021; no EU GMP certification found. |
TransData Nexus reviewed the regulatory standing of 5 leading Sulfadoxine exporters from India. 0 hold US FDA facility approvals, 5 maintain WHO-GMP certification, and 2 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Sulfadoxine sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," hosts over 800 pharmaceutical companies, including major players like Dr. Reddy’s Laboratories and Aurobindo Pharma. The city's Genome Valley is India's first biotech cluster, fostering advanced R&D infrastructure and a skilled talent pool. Hyderabad's specialization in active pharmaceutical ingredients (APIs), vaccines, and biologics positions it as a strategic hub for bulk drug manufacturing.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat contributes nearly 28% of India's pharmaceutical production. This region is home to industry leaders such as Zydus Cadila and Torrent Pharmaceuticals. With a strong support infrastructure, including ports and roads, and a focus on formulations and APIs, this cluster is pivotal for pharmaceutical manufacturing and exports.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad region serves as a critical hub for pharmaceutical manufacturing, innovation, and exports. This area contributes approximately 25-30% of India's total pharmaceutical output and houses over 40% of the nation's pharmaceutical R&D centers. The presence of major ports facilitates efficient export logistics, enhancing the region's role as a gateway for pharmaceutical exports.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi, located in Himachal Pradesh, is recognized as Asia's largest pharmaceutical hub, housing over 1,000 pharmaceutical companies. The region's growth has been driven by favorable government policies, including tax incentives and excise duty exemptions, which have attracted numerous pharmaceutical manufacturers. Baddi's strategic location and robust infrastructure make it a key player in India's pharmaceutical landscape.
5Sourcing Recommendations
- Diversify Supplier Base: While S KANT HEALTHCARE LIMITED dominates Sulfadoxine exports, consider engaging with other suppliers to mitigate risks associated with over-reliance on a single source.
- Leverage Regional Specializations: Utilize Hyderabad's expertise in bulk drug manufacturing and Ahmedabad-Vadodara's strength in formulations to optimize sourcing strategies.
- Optimize Export Logistics: Capitalize on the Mumbai-Thane-Raigad region's port facilities to enhance export efficiency and reduce lead times.
- Monitor Regulatory Compliance: Ensure all suppliers adhere to international quality standards and regulatory requirements to maintain product integrity and market access.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Sulfadoxine exporters from India
S KANT HEALTHCARE LIMITED — WHO prequalifies S Kant's Pyrimethamine/Sulfadoxine tablet
The World Health Organization (WHO) granted prequalification to S Kant Healthcare Ltd. for their Pyrimethamine/Sulfadoxine 25mg/500mg tablet, indicating compliance with international quality standards. (extranet.who.int) - IMPACT: This approval is expected to enhance S Kant's credibility and potentially increase Sulfadoxine exports.
Impact: This approval is expected to enhance S Kant's credibility and potentially increase Sulfadoxine exports.
S KANT HEALTHCARE LIMITED — WHO prequalifies S Kant's Pyridoxine hydrochloride tablet
WHO prequalified S Kant Healthcare Ltd.'s Pyridoxine hydrochloride 50mg film-coated tablet, affirming its adherence to global quality standards. (extranet.who.int) - IMPACT: While not directly related to Sulfadoxine, this approval may bolster the company's overall export portfolio.
Impact: While not directly related to Sulfadoxine, this approval may bolster the company's overall export portfolio.
S KANT HEALTHCARE LIMITED — Acuité upgrades S Kant Healthcare's credit rating
Acuité Ratings & Research upgraded S Kant Healthcare Ltd.'s long-term rating to 'ACUITE A' and short-term rating to 'ACUITE A1', reflecting improved financial performance and operational stability. - IMPACT: The enhanced credit rating may facilitate better financing options, potentially supporting increased Sulfadoxine production and exports.
Impact: The enhanced credit rating may facilitate better financing options, potentially supporting increased Sulfadoxine production and exports.
Common Questions — Sulfadoxine Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which sulfadoxine supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, S KANT HEALTHCARE LIMITED leads with 103 recorded shipments worth $37.5M. MACLEODS PHARMACEUTICALS LTD (34 shipments) and GRACURE PHARMACEUTICALS LIMITED (39 shipments) are also established high-volume exporters.
Q How many sulfadoxine manufacturers are there in India?
India has 41 active sulfadoxine exporters with a combined export market of $54.0M across 364 shipments to 38 countries. The top 5 suppliers hold 84.1% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for sulfadoxine from India?
Average FOB unit price: $15.97 per unit, ranging from $0.04 to $269.91. Average shipment value: $148.4K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 41 verified Indian exporters of Sulfadoxine ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 364 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 38 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
364 Verified Shipments
41 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists